Cosma Meda, Mocan Teodora, Delcea Cristian, Pop Teodora, Mosteanu Ofelia, Mocan Lucian
Department of Physiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania.
Department of Forensic Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj Napoca, Romania.
Int J Mol Sci. 2025 Aug 16;26(16):7917. doi: 10.3390/ijms26167917.
Hepatocellular carcinoma (HC) ranks as the fifth most prevalent form of cancer among humans and is a significant contributor to cancer-related deaths. During the latest year, an interesting scientific fascination arose around gold nanoparticles (AUNPs) following the recovery of their remarkable properties. Some studies suggest that AUNPs can enhance drug targeting in cancer treatment and reduce its toxicity. The major purpose of this paper is to systematically review the effectiveness, safety, and prospective mechanism of gold nanoparticles in delivering drugs for liver cancer treatment. Comprehensive research was conducted using major scientific databases (i.e., PubMed, Web of Science, and Scopus) to identify studies focusing on AUNPs in drug delivery systems. We mainly focused on studies that specifically analyzed liver cancer. The current results of the systematic review show that the application of gold nanoparticles (AUNPs) in liver cancer drug delivery enhances drug targeting to liver tumors. This efficient factor improves the bioavailability and elevates the therapeutic index of chemotherapeutic agents in treatment. This systematic review highlights the significant potential of AUNPs to increase the delivery of drugs for liver cancer treatment effectively. The major findings indicate that AUNPs improve the targeting and bioavailability of chemotherapeutic agents, enhancing therapeutic outcomes such as tumor suppression and improved survival rates. While the results of this review are encouraging; however, further research is necessary to ensure the safety and efficacy of AUNPs in clinical settings. Human trials must address concerns regarding long-term toxicity and regulatory approval.
肝细胞癌（HC）是人类中第五大最常见的癌症形式，并且是癌症相关死亡的重要原因。在最近一年，随着金纳米颗粒（AUNPs）卓越性能的发现，引发了科学界的浓厚兴趣。一些研究表明，AUNPs在癌症治疗中可增强药物靶向性并降低其毒性。本文的主要目的是系统综述金纳米颗粒在肝癌治疗药物递送中的有效性、安全性及潜在机制。利用主要科学数据库（即PubMed、科学网和Scopus）进行了全面研究，以识别聚焦于AUNPs在药物递送系统中的研究。我们主要关注专门分析肝癌的研究。系统综述的当前结果表明，金纳米颗粒（AUNPs）在肝癌药物递送中的应用增强了对肝肿瘤的药物靶向性。这一有效因素提高了生物利用度，并提升了化疗药物在治疗中的治疗指数。本系统综述突出了AUNPs在有效增加肝癌治疗药物递送方面的巨大潜力。主要研究结果表明，AUNPs提高了化疗药物的靶向性和生物利用度，增强了诸如肿瘤抑制和提高生存率等治疗效果。虽然本综述的结果令人鼓舞；然而，有必要进一步研究以确保AUNPs在临床环境中的安全性和有效性。人体试验必须解决有关长期毒性和监管批准的问题。
